Guide · Updated November 2026

Survodutide: The GLP-1/Glucagon Agonist for Fatty Liver

Survodutide is an investigational dual GLP-1 and glucagon receptor agonist from Boehringer Ingelheim, licensed from Zealand Pharma, for metabolic dysfunction-associated steatohepatitis (MASH) and obesity. In a 48-week phase 2 MASH trial, 62% of people on the 4.8 mg dose had MASH improvement without worse fibrosis, versus 14% on placebo (NEJM, 2024). It is not FDA-approved. The phase 3 MASH trials are still running.

Survodutide is one of several drugs that pair GLP-1 with a second hormone target. Its phase 2 MASH results were published in the New England Journal of Medicine in 2024, and its first phase 3 obesity results came out in 2026.

I have been tracking the GLP-1 space closely since starting Mounjaro for body composition reasons and monitoring my results with DEXA scans. Survodutide is not available yet, but the data behind it is worth understanding, especially if you care about metabolic health beyond the number on the scale.

What Is Survodutide and How Does It Work?

Survodutide (formerly BI 456906) activates two receptors: the GLP-1 receptor and the glucagon receptor. Semaglutide works through the GLP-1 receptor. Tirzepatide adds GIP receptor activation on top of that. Survodutide takes a different path by pairing GLP-1 with glucagon.

Why glucagon? It sounds counterintuitive. Glucagon raises blood sugar, which is the opposite of what you want in a diabetes drug. The rationale is that glucagon signaling also acts on the liver and on energy use, and the trial authors tested whether dual agonism works better for MASH than GLP-1 agonism alone (NEJM, 2024).

The proposed combination:

• GLP-1 activation reduces appetite and slows gastric emptying (the same mechanism behind Ozempic and Wegovy)
• Glucagon activation is expected to act directly on liver fat and energy expenditure
• Together, they aim at both liver fat and the excess calories that feed it

MASH is a condition where excess liver fat triggers inflammation and scarring (fibrosis). None of the approved GLP-1 medications act on the glucagon receptor.

Survodutide Phase 2 MASH Trial Results

The phase 2 MASH trial was a 48-week, randomized, double-blind, placebo-controlled study in 293 adults with biopsy-confirmed MASH and fibrosis stages F1 through F3. It had a 24-week rapid dose escalation phase followed by a 24-week maintenance phase (NEJM, 2024).

The headline numbers from the published abstract:

For context, resmetirom (Rezdiffra) became the first FDA-approved MASH drug on March 14, 2024. In its trial, 26% to 27% on 80 mg and 24% to 36% on 100 mg had NASH resolution without worse scarring, versus 9% to 13% on placebo. The endpoints and trial designs differ, so do not compare these numbers head to head. Resmetirom is no longer the only option. Wegovy now carries an FDA indication for noncirrhotic MASH with moderate to advanced fibrosis (Wegovy label).

What About Fibrosis Specifically?

Fibrosis improvement was more modest: 36% on survodutide 4.8 mg versus 22% on placebo. Fibrosis takes longer to change than liver fat, so a 48-week trial may be too short to show the full effect. The phase 3 LIVERAGE trial measures MASH and fibrosis at week 52 and follows outcomes for up to 7 years (ClinicalTrials.gov).

Survodutide Weight Loss Data

Survodutide was also tested for obesity in a phase 2 dose-finding trial published in The Lancet Diabetes & Endocrinology in 2024. It ran 46 weeks (20 weeks of dose escalation, 26 weeks of maintenance) in 386 treated adults with a BMI of 27 or higher and no diabetes (Lancet Diabetes Endocrinol, 2024).

Mean weight change at week 46 by planned dose:

Only 60.4% of participants completed the 46-week treatment period, and gastrointestinal adverse events hit 75% of survodutide recipients versus 42% on placebo.

How Does This Compare to Other GLP-1s?

STEP 1 reported 14.9% with semaglutide 2.4 mg at 68 weeks (NEJM, 2021). SURMOUNT-1 reported 20.9% with tirzepatide 15 mg at 72 weeks (NEJM, 2022). Retatrutide reached 24.2% at 48 weeks on 12 mg in its phase 2 trial (NEJM, 2023). These are separate trials with different populations, so treat the comparison as rough.

On weight loss alone, survodutide’s phase 3 numbers came in below tirzepatide’s. Its case rests on the liver data. If you only care about losing weight, approved options exist today. If you have fatty liver disease, the MASH phase 3 results are the ones to watch.

Side Effects: The Honest Picture

Survodutide’s GI side effect rates were high in phase 2. This is the part of the story that does not get enough attention.

In the phase 2 MASH trial, adverse events that were more frequent with survodutide included (NEJM, 2024):

For comparison, the Zepbound label reports nausea in 25% to 29% of tirzepatide patients versus 8% on placebo (Zepbound label), and the Wegovy label reports 44% versus 16%. Different trials, but survodutide’s 66% nausea rate stands out.

Serious adverse events occurred at similar rates on survodutide (8%) and placebo (7%) in the MASH trial. The phase 2 trial used a 24-week rapid escalation schedule. The phase 3 SYNCHRONIZE-1 trial allowed extended dose escalation periods, and GI adverse events were still reported in 81% to 90% of survodutide patients versus 48% on placebo, mostly mild to moderate (ACC summary of SYNCHRONIZE-1).

If you have experience with GLP-1 side effects, you know the pattern: GI symptoms tend to be worst during dose increases.

Phase 3 Trials: What to Watch For

For obesity (SYNCHRONIZE program):

• SYNCHRONIZE-1 (725 adults with obesity, no diabetes): published in NEJM in June 2026. At 76 weeks, mean weight change was about 12% on 3.6 mg and 13% on 6.0 mg versus about 5% on placebo in the main treatment-regimen analysis (ACC). The 16.6% figure in company announcements is the efficacy estimand, which assumes people stayed on treatment.
• SYNCHRONIZE-2 (obesity with type 2 diabetes): announced October 1, 2026, with weight loss of up to 13.1% at 76 weeks (Clinical Trial Vanguard).
• SYNCHRONIZE-CVOT: a cardiovascular outcomes trial. Zealand Pharma said in August 2026 that results are expected later in 2026 (Zealand H1 2026 report).

For MASH (LIVERAGE program):

• LIVERAGE: about 1,800 adults with MASH and moderate or advanced fibrosis. It measures MASH and fibrosis at week 52 and liver outcomes for up to 7 years. Estimated primary completion is December 2031 (ClinicalTrials.gov).
• LIVERAGE-Cirrhosis: about 1,590 adults with MASH and compensated cirrhosis, followed for up to 4.5 years. Estimated primary completion is June 2029 (ClinicalTrials.gov).

In October 2024, Zealand announced that the FDA granted survodutide Breakthrough Therapy designation for noncirrhotic MASH with moderate or advanced fibrosis (ConsultantLive). The designation can speed up review but does not guarantee approval.

The obesity results are in and came in below tirzepatide. The MASH trials have not reported yet, and there is no approval date for either use.

Survodutide vs. the Next-Gen GLP-1 Pipeline

Sources: Lilly’s TRIUMPH-4 topline, the amycretin Lancet paper and phase 3 listing, Altimmune’s December 2025 release, and the REDEFINE 1 paper. Different populations and durations, so these are not head-to-head results.

Retatrutide is the closest competitor because it also activates the glucagon receptor (plus GIP). It has produced larger weight loss so far. Pemvidutide is another GLP-1/glucagon dual agonist. Altimmune reported 48-week phase 2b MASH data in December 2025 and said it plans to start a phase 3 MASH trial in 2026.

Who Might Benefit Most from Survodutide?

If it is approved, survodutide looks most relevant for:

1. People with MASH who need liver-targeted treatment
2. People with elevated liver enzymes (ALT/AST) and obesity, after a doctor confirms the cause
3. People who respond to GLP-1 therapy but still have liver disease

If you do not have fatty liver disease and your primary goal is weight loss, the currently available options (Mounjaro, Zepbound, or Wegovy) are more relevant. You can compare them in our medication comparison guide or check the cheapest ways to access GLP-1 medications right now.

For those tracking body composition closely, DEXA scans track overall lean vs. fat mass, but they do not measure liver fat. Ask your doctor about imaging such as ultrasound or FibroScan if liver fat is the concern.

The Bottom Line

Survodutide’s phase 2 MASH data was strong on its primary endpoint: 62% improvement at 4.8 mg versus 14% on placebo. The GI side effects were heavy in phase 2 and remained common in phase 3. The obesity phase 3 trials reported in 2026, the MASH phase 3 trials have not, and there is no approval date.

If you have fatty liver disease today, talk to your doctor about current options, including the two FDA-approved MASH treatments. If you are already on a GLP-1 and want to monitor your metabolic health, tracking your body composition with our body composition calculator is a good starting point.

FAQ

This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any medication. ClearMetabolic may earn a commission through provider links on this page. See our full disclosure.

Related

Guides:

• Cheapest GLP-1 Online · Side Effects Guide · Body Composition Guide
• Amycretin vs Tirzepatide · DEXA Scan Results · Insurance Coverage

Provider Reviews: Ro · Hims · MEDVi

Compare: All Providers · Best GLP-1 Programs · All Guides

What we checked

This AI-assisted public-source desk check reviewed the published phase 2 survodutide papers in NEJM and The Lancet Diabetes & Endocrinology, ClinicalTrials.gov listings, the FDA resmetirom announcement, the Wegovy and Zepbound labels, Zealand Pharma’s H1 2026 report, and published summaries of the phase 3 results on November 4, 2026. This is not a clinical review and it is not medical advice. Prices and policies change, so confirm them with the provider or your prescriber before you act.